Erlotinib 100 mg/d was comparable to gefitinib 250 mg/d in terms of disease control, tumor response, PFS, OS, and toxicity, supporting the use of 100 mg/d erlotinib in patients with EGFR-mutated, advanced NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.